Loading...
•
Dec 31, 2019
Veracyte Q4 2019 Earnings Report
Achieved revenue growth and positive cash flow, strategically positioned for global expansion through acquisition.
Key Takeaways
Veracyte reported a 15% increase in total revenue for Q4 2019, reaching $29.7 million. The company achieved cash flow breakeven status and acquired global diagnostic rights to the NanoString nCounter FLEX Analysis System.
Total revenue increased by 15% to $29.7 million.
Gross margin remained unchanged at 66%.
Net loss increased by 140% to ($7.5) million.
Cash and cash equivalents were $159.3 million at the end of the quarter.
Revenue by Segment
Forward Guidance
Veracyte anticipates full-year 2020 total revenue to range between $138 million and $142 million, with net cash used in operating activities expected to be between $8 million and $12 million.
Revenue & Expenses
Visualization of income flow from segment revenue to net income
Historical Earnings Impact
Analyze how earnings announcements historically affect stock price performance
Avg. Return Before/After Earnings
Loading earnings performance data...
Loading earnings reaction data...